Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses
Julianna Blagih, Fabio Zani, Probir Chakravarty, Marc Hennequart, Steven E. Pilley, Sebastijan Hobor, Andreas Hock, Josephine Walton, Jennifer P. Morton, Eva Grönroos, Susan Mason, Ming Yang, Iain A. McNeish, Charles Swanton, Karen Blyth, Karen H. Vousden
Abstract
T cell responses in vivo. p53-null tumors also show an accumulation of suppressive regulatory T (Treg) cells. Finally, we show that two key drivers of tumorigenesis, activation of KRAS and deletion of p53, cooperate to promote immune tolerance.
Topics & Concepts
Immune systemBiologyCancer researchCD8T cellMyeloidChemokineCarcinogenesisImmunologyCancerGeneticsImmune cells in cancerCancer Immunotherapy and BiomarkersImmune Cell Function and Interaction